Navigation Links
TWi Pharmaceuticals Announces That It Will Sell Its Products in the U.S. Market, Originally Planned to Be Sold by Teva, Through Its Wholly-Owned Subsidiary, TWi Pharmaceuticals USA
Date:2/23/2015

TAIPEI, Feb. 23, 2015 /PRNewswire/ -- TWi Pharmaceuticals, Inc. ("TWi") (4180:Taiwan) today announced that TWi and Teva Pharmaceuticals ("Teva") have reached an agreement that will transfer the United States (U.S.) sales and distribution rights of TWi's generic versions of Megace® ES (megestrol acetate oral suspension, 625 mg/ 5 ml) and Lidoderm® (lidocaine patch, 5%) from Teva to TWi. TWi will distribute both products through its wholly-owned subsidiary, TWi Pharmaceuticals USA.

TWi has assembled a sales and distribution team in the U.S. and plans to launch several products in the U.S. under TWi's label this year.

"We are excited that we are going to sell our products under the TWi label and TWi will be able to enjoy all the profits derived from the products. We are optimistic about the change, which is consistent with the company strategy," said Dr. Calvin Chen, President of TWi Pharmaceuticals, Inc.

About TWi Pharmaceuticals, Inc.

TWi Pharmaceuticals, Inc. is a leading specialty pharmaceutical company based in Taipei, Taiwan, focusing on the development of high barrier generic prescription products ranging from oral controlled release dosage form to novel drug delivery systems including the utilization of nanoparticles, transdermal, and polymeric oral delivery systems. Leveraging its internal research and development capabilities, together with operational flexibility, process development, manufacturing and regulatory expertise, TWi Pharmaceuticals concentrates on products and technologies that present significant barriers to entry or offer Paragraph IV first-to-file or first-to-market opportunities in the United States. For more information of TWi Pharmaceuticals, please visit www.twipharma.com.

Contact :
Eric Lin 
Tel: +886-2-2657-3350 #407
email: eric.lin@twipharma.com


'/>"/>
SOURCE TWi Pharmaceuticals, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
2. Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeants Board of Directors
3. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
4. Access Pharmaceuticals Reports First Quarter Results
5. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
6. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
7. AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
8. Aveo Pharmaceuticals, Inc. Sued by Investor
9. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm
10. Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology
11. Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2019)... ... ... in complex industries, a former Procter & Gamble Vice President learned that just knowing his ... turned a make-it-or-break-it opportunity — debating his company’s biggest critic on live TV — into ... September 9, 2019 at 12pm EDT (5pm BST/UK), join 3D Executive Communications expert ...
(Date:8/19/2019)... ... August 19, 2019 , ... ... Spiro Khoury, M.D., will join its Richardson, Texas location, starting Monday, Sep. 2nd. ... of Anesthesiology with a subspecialty board certification in pain management. , Dr. Khoury ...
(Date:8/17/2019)... , ... August 17, 2019 , ... ... Inc. 5000 , Foster Crown, LLC Ranks No. 2502 on the 2019 Inc. ... that Foster Crown, LLC, the boutique physician recruitment firm is No. 2502 on ...
Breaking Medicine Technology:
(Date:8/14/2019)... ... August 15, 2019 , ... R3 Stem Cell ... R3 Stem Cell International is offering regenerative procedures with mesenchymal stem cells performed ... procedure costs only $2950, which includes a complete IV therapy or two joint ...
(Date:8/14/2019)... ... August 13, 2019 , ... Dr. Rachel ... Beauty network. , The Haute Beauty Network, well known for its exclusive and ... leading aesthetic medicine expert and our newest addition to the Haute Beauty members-only ...
(Date:8/14/2019)... (PRWEB) , ... August 13, 2019 , ... New ... P. Falaschi, vice president of operations and information technology, and Elie Goldstein, vice president ... as part of New U Life’s commitment to expanding its corporate governance. , “Since ...
(Date:8/14/2019)... ... August 14, 2019 , ... Today, consumers are taking a harder look ... their physical body, emotions and energy levels. The trick is finding food and beverages ... , That’s why founder Chris Harper created Chase – a delicious, guilt ...
(Date:8/12/2019)... ... August 12, 2019 , ... Cryotherapy has recently been the ... the Oakland Raiders. However, the cause of Brown’s injury was not due to cryotherapy, ... cryotherapy session. Numerous NFL teams, such as the Dallas Cowboys, the Washington Redskins, the ...
Breaking Medicine News(10 mins):